FDA Adds Limbic as Third Name in Its TEMPO Device Pilot

The FDA has quietly added behavioral health company Limbic as the third named participant in its TEMPO pilot for digital health devices, joining remote monitoring firm Cadence and continuous glucose monitor maker Dexcom, whose shares traded at 90.86, up 1.09%, as of 16:31 GMT on Aug. 20, 2026.

The Food and Drug Administration has added a third company to the roster of its TEMPO pilot, and it did so the way it has handled the programme so far: without a press release. Behavioral health company Limbic now appears on the pilot's webpage alongside remote patient monitoring firm Cadence and Dexcom (DXCM), the continuous glucose monitor maker, according to Endpoints News, which tracked the additions as they appeared.

Three names is not a policy. But the composition of those three names tells you something about what the agency is trying to learn, and the quiet manner of the rollout tells you something about how confident it is that it already knows the answer.

Three companies, three different regulatory problems

The participants selected so far do not look like a single product category. Dexcom sells hardware that sits on a patient's body and streams data continuously — a device with a long, well-established regulatory history and an installed base. Cadence works in remote monitoring, where the product is less a physical object than a service wrapped around data collection between clinic visits. Limbic operates in behavioral health, the corner of digital health where software often acts closest to a clinician's judgment and where the evidence base is hardest to standardise.

Put those three together and you have a reasonable cross-section of the problem the FDA faces with digital health: a category in which the thing being regulated changes after it is cleared. A drug approved in one formulation stays that formulation. A software-driven device can be updated weekly, and each update is, in principle, a change to the cleared product. Traditional premarket review was not designed for that cadence.

What 'try first, evaluate later' would actually change

The framing attached to TEMPO — try first, evaluate later — describes a sequencing change rather than a lowering of the bar. In a conventional device pathway, the bulk of the evidence has to exist before the product reaches users. Shifting weight toward post-deployment evaluation means a product can be put in front of patients earlier, with the evidence obligation continuing rather than concluding at the moment of clearance.

For a device maker, that reordering hits three things at once:

• Time to first revenue. The gap between finishing a product and being allowed to sell it is where digital health companies burn cash. Compressing it changes the size of the round you need to raise.
• The nature of the evidence. Real-world data collected from deployed users is cheaper to gather than a purpose-built trial, but noisier and harder to control. Companies would need infrastructure to capture it continuously, not a one-off study budget.
• The tail risk. If evaluation happens after launch, the possibility of an adverse finding arrives after commercial commitments have been made — sales teams hired, health-system contracts signed. That is a different risk profile for an investor to underwrite.

None of this is settled from three webpage entries. What can be said is that the FDA is testing the mechanics on live companies before writing the rules, which is itself a departure from guidance-first practice.

Dexcom is the outlier on the list

Two of the three participants are private-market names in categories where regulatory clarity is scarce. Dexcom is neither. It is a listed company with an approved product line and a commercial footprint, which makes its presence on the pilot list the most informative single data point available.

A large incumbent does not join a regulatory pilot to shorten the path for a product it has already cleared. It joins to shape the framework that will govern the next generation of its devices — and, not incidentally, to be in the room when the FDA decides what evidence a software-updating sensor has to produce. For the smaller participants, TEMPO is a route to market. For Dexcom, it is closer to standard-setting.

The market has not treated the news as a catalyst. Dexcom shares changed hands at 90.86 as of the last trade at 16:31 GMT on Aug. 20, 2026, up 1.09% from the previous close of 89.88, having traded between 89.28 and 91.40 on the day. That is a modest gain against a broadly soft session: the S&P 500 tracker SPY was at $765.52, down 0.46%, the Nasdaq 100 tracker QQQ at $711.33, down 0.66%, and the Dow tracker DIA at $529.63, down 0.87%. Outperforming a down tape by a point is not a re-rating, but it is not indifference either.

Why the silence around the pilot matters

Regulatory programmes normally arrive with a launch event, a docket and a comment period. TEMPO's participant list has instead been assembled by adding names to a webpage. There are benign readings of that — a pilot with a handful of participants does not need a communications campaign, and the agency may want room to change course without having publicly committed to a design.

There are less comfortable readings too. Companies not selected have no visible criteria to work against. Payers and health systems, who ultimately decide whether a digital health product gets used, have no formal statement to evaluate. And clinicians asked to deploy a product whose evaluation is still running will want to know what 'later' means in practice.

What to watch from here

The webpage itself is the disclosure channel, so the first thing to watch is simply who is added next — and whether the additions keep spanning categories or start to cluster around one type of product. A fourth and fifth participant drawn from behavioral health software would suggest the agency has narrowed its question.

Beyond that: whether any participant discloses what obligations it has taken on, whether the FDA publishes criteria or a formal framework, and whether a listed participant ever cites TEMPO in guidance as a reason its regulatory timeline moved. Until one of those happens, the pilot remains what it currently is — three names, quietly posted, on a page most of the market has not read.

Key facts

• Pilot participants named so far: Dexcom, Cadence, Limbic (three)
• Newest addition: Limbic, a behavioral health company
• DXCM last trade: 90.86, +1.09% (16:31 GMT, Aug 20, 2026)
• DXCM day range: 89.28–91.40, prev close 89.88

Frequently asked questions

Who are the three companies in the FDA's TEMPO pilot?

As of Aug. 20, 2026, three participants appear on the pilot's webpage: continuous glucose monitor maker Dexcom, remote patient monitoring company Cadence, and behavioral health company Limbic. Limbic is the most recent addition. The FDA has been selecting participants quietly, posting names to the page rather than announcing them through a formal release.

What does 'try first, evaluate later' mean for a device maker?

It describes shifting the weight of evidence-gathering from before market entry to after it. Rather than completing the bulk of evaluation ahead of clearance, a product could reach users earlier with the evidence obligation continuing in real-world use. That changes time to first revenue, the type of data a company must collect, and when regulatory risk lands.

How did Dexcom shares trade on the day Limbic was added?

Dexcom traded at 90.86 as of the last trade at 16:31 GMT on Aug. 20, 2026, up 1.09% from a previous close of 89.88, with a day range of 89.28 to 91.40. That was a modest gain against a weaker broad market, where the S&P 500 tracker fell 0.46% and the Nasdaq 100 tracker fell 0.66%.

Why would an established company like Dexcom join a regulatory pilot?

A company with cleared products and existing revenue gains less from a faster route to market than a start-up does. The likelier motivation is influence over the framework that will govern future software-updating devices — being present while the FDA determines what evidence such products must generate, rather than adapting to rules written without input.

Is TEMPO a formal regulatory pathway yet?

No. Based on what is publicly visible, it is a pilot with a small number of selected participants, communicated through additions to an FDA webpage rather than a published framework with stated selection criteria. Whether it becomes a durable pathway depends on results the agency has not yet released and rules it has not yet written.

Why is digital health hard to regulate under existing device rules?

Traditional premarket review assumes the cleared product stays fixed. Software-driven devices are updated continuously, so each release is arguably a change to what was approved. That mismatch pushes regulators toward frameworks that evaluate products over time in real use rather than at a single point before launch.

Sources

• Try first, evaluate later: How the FDA is approaching digital health devices — Endpoints News

Photo: Pavel Danilyuk · Pexels Licence — source